Featured Story | By Ben Adams After nabbing $230 million at the start of the year, “gene writing” biotech Tessera Therapeutics has boosted its management and research team, including poaching bluebird bio’s chief medical officer. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Novartis has struck a deal with Artios Pharma to access DNA damage response (DDR) targets with the potential to enhance its radioligand therapies. Artios, which is run by some of the people behind pioneering DDR drug Lynparza, is set to get $20 million upfront and up to $1.3 billion in milestones in return for the targets. read more By Nick Paul Taylor Icosavax has raised $100 million to study viruslike particle vaccines against diseases including respiratory syncytial virus and COVID-19. The series B round equips Icosavax to take two assets into clinical trials this year. read more Sponsored By: BioIVT Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are common pathologies without specialized therapeutics, but new models may provide opportunities for drug discovery. read more By Ben Adams Metagenomi has added a cool $10 million extra to its January series A funding round with help from RA Capital as it also adds the VC firm’s M.D. to the board. read more By Amirah Al Idrus Bristol Myers Squibb and PsiOxus are expanding their partnership—again. The duo first teamed up in June 2016 to study the latter’s cancer-killing virus, inking a deal later that year to combine the virus with BMS’ checkpoint inhibitor, Opdivo. Now, they’re adding a second asset from PsiOxus to the mix. read more By Conor Hale Pear Therapeutics is building out its app-based digital treatment platform into something a little more tangible with the addition of wearable sensors and activity trackers. read more By Angus Liu In a stunning revelation, FibroGen admitted to presenting roxadustat data manipulated to make the anemia drug look safer than it is. The late-Tuesday announcement sent FibroGen shares tumbling and prompted analysts to reassess the potential first-in-class therapy ahead of an FDA decision. read more Resources Sponsored By: August Bioservices How has COVID-19 impacted CRO/CDMO customer (dis)satisfaction and outsourcing decisions for pharma and biotech companies in 2021 and beyond? Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored by: PerkinElmer Informatics Discover the benefits of a cloud-native ELN that delivers better performance, security, connectivity, total cost of ownership PLUS sub-second search results through even the largest data volumes. Sponsored By: OCT Clinical Find out why more than 400 clinical trials annually are initiated in Russia by US and EU pharma in the free annual report by OCT Clinical. Sponsored by: PulsePoint Access this guide for the latest insights into how marketers can use data, technology, and personalized messaging to build vaccine confidence and drive successful immunization efforts. Sponsored By: Within3 We enable virtual work — offering over-time sessions where participants are more focused, insights are more diverse and business goals are met. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: TAC Roche has inked a $1.8 billion, all-cash deal for GenMark Diagnostics, to acquire its molecular tests designed to screen patient samples for multiple infections simultaneously. Sponsored By: Almac Clinical Technologies This industry report reveals qualitative and quantitative candid insight from clinical development insiders and their views on current clinical trial challenges faced amidst uncertainty. Sponsored By: Remarque Systems Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. Sponsored By: Culture Biosciences Find out how upstream bioprocess scientists can use Culture Biosciences’ bioreactor system and real-time data visualizations to get faster insights and get their product to market more quickly. Sponsored By: BC Platforms Those wishing to unlock RWD’s true value must have access to a variety of data sources/types and the technological capabilities to use the data to uncover meaningful insights. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: Catalent Autologous cell therapies have seen propelled growth since 2017, with the spotlight on the first FDA approval of a chimeric antigen receptor (CAR) T cell immunotherapy, Kymriah® (tisagenlecleucel), for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. | 
